Prostatilen effects on voiding disorders in patients with benign prostatic hyperplasia
- Autores: Al-Shukri SK.1, Gorbachev AG1, Borovets SY.1, Belousov VY.1, Kuzmin IV1
-
Afiliações:
- Edição: Nº 5 (2005)
- Páginas: 25-26
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/276612
- ID: 276612
Citar
Texto integral
Resumo
The authors review the experience with prostatilen treatment gained in the urological clinic of the St-Petersburg State Medical University and analyze treatment outcomes for 96 patients with benign prostatic hyperplasia (BPH) aged from 51 to 89 years. Prostatilen proved its efficacy in relieving manifestations of infravesical obstruction in BPH, therefore, prostatilen administration in the treatment of patients with initial or moderate subjective and objective symptoms is justified. Dimexide suppositoria containing 30 mg of prostatilen are preferable.
Bibliografia
- Аль-Шукри С. X., Горбачев А. Г., Кузьмин И. В., Хавинсон В. X. Введение в биорегулируюшую терапию при урологических болезнях. СПб.: Наука; 1996.
- Aib-Шукри С. X., Бобков Ю. А., Горбачев А. Г. и др. Применение простатилена в урологии. Урология 2003; 6: 32-36.
- Агъ-Шукри С. X., Барабанов С. В., Барабанова В. В. и др. Влияние пептидов предстательной железы на сократительную активность гладкомышечных клеток кровеносных сосудов и мочевого пузыря кошек. Физиол. журн. 1996; 7: 99-104.
Arquivos suplementares
